Search
Protara Therapeutics Inc
TARAAdd to Watchlist
4.000USD
-0.030-0.74%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
224.82MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-25The current earnings forecast score of Protara Therapeutics Inc is 8.25, ranking 146 out of 387 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 30.00 and a low of 21.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
26.667
Target Price
+566.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Protara Therapeutics Inc
TARA
8
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Protara Therapeutics Inc's price target?
Analysts forecast that Protara Therapeutics Inc's price target is USD 25.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 21.00.
How have Protara Therapeutics IncTARA's recent earnings per share performed?
The market expectation was USD -0.31, while Protara Therapeutics IncTARA's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.33.
What is the analyst rating for Protara Therapeutics Inc?
Based on the ratings of Protara Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
